Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of SpringWorks Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
- Summary
-
SpringWorks Therapeutics, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
- SpringWorks Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Mar 2025 was $5,975,000, a 90% increase year-over-year.
- SpringWorks Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $106,291,000, a 198% decline from 2023.
- SpringWorks Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $108,598,000.
- SpringWorks Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $36,458,000, a 15% increase from 2021.
- Source SEC data
- View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
SpringWorks Therapeutics, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2025 | $5,975,000 | +$52,044,000 | +90% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 09 May 2025 | 2025 | Q1 | |
| Q1 2024 | $58,019,000 | -$92,957,000 | -266% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 09 May 2025 | 2025 | Q1 | |
| Q1 2023 | $34,938,000 | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 02 May 2024 | 2024 | Q1 |
SpringWorks Therapeutics, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | $106,291,000 | -$214,889,000 | -198% | 01 Jan 2024 | 31 Dec 2024 | 10-K | 20 Feb 2025 | 2024 | FY |
| 2023 | $108,598,000 | +$145,056,000 | 01 Jan 2023 | 31 Dec 2023 | 10-K | 20 Feb 2025 | 2024 | FY | |
| 2022 | $36,458,000 | +$6,670,000 | +15% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 20 Feb 2025 | 2024 | FY |
| 2021 | $43,128,000 | +$137,410,000 | +76% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 27 Feb 2024 | 2023 | FY |
| 2020 | $180,538,000 | -$462,542,000 | -164% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 28 Feb 2023 | 2022 | FY |
| 2019 | $282,004,000 | 01 Jan 2019 | 31 Dec 2019 | 10-K | 24 Feb 2022 | 2021 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.